Oxford, UK - 24 January 2007: Oxford BioMedica (LSE: OXB), a leading gene therapy company, and its collaborative partners in the field of avian transgenics, Viragen, Inc. (AMEX: VRA) and Roslin Institute, today announced a new achievement with the successful expression of human interferon alpha-2a in the whites of eggs laid by transgenic hens using the OVA™ System (Avian Transgenic Biomanufacturing). This is the third therapeutic protein expressed thus far in a series of “proof-of-principle” studies, which aim to develop the OVA™ System as a novel, large-scale biomanufacturing alternative capable of cost-effectively expressing many types of therapeutic proteins. Viragen holds the worldwide exclusive license to commercialise Avian Transgenic Technology as granted by Roslin Institute.
